Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022. Issue 2 (9th January 2023)

• Record Type: Journal Article
• Authors: Stoliaroff-Pepin, Anna; Peine, Caroline; Herath, Tim; Lachmann, Johannes; Perriat, Delphine; Dörre, Achim; Nitsche, Andreas; Michel, Janine; Grossegesse, Marica; Hofmann, Natalie; Rinner, Thomas; Kohl, Claudia; Brinkmann, Annika; Meyer, Tanja; Dorner, Brigitte G.; Stern, Daniel; Treindl, Fridolin; Hein, Sascha; Werel, Laura; Hildt, Eberhard; Gläser, Sven; Schühlen, Helmut; Isner, Caroline; Peric, Alexander; Ghouzi, Ammar; Reichardt, Annette; Janneck, Matthias; Lock, Guntram; Schaade, Lars; Wichmann, Ole; Harder, Thomas;
• Is Part Of: Vaccine. Volume 41:Issue 2(2023)
• Page Start: 290
• Page End: 293
• Publication Date: 2023-01-09
• Subjects: COVID-19 -- Vaccine effectiveness -- Hospitalization -- Case-control study -- SARS-CoV-2 -- Delta; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.11.065
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: This study assesses detailed first-hand data and therefore provides a very high data quality. Detailed interviews, abstraction of medical records and laboratory analyses were combined to obtain comprehensive data sets. More than half of the cases (58 %) were not vaccinated at all, compared to 11 % of the controls. The vaccine effictiveness to prevent severe disease in the Delta wave was 89 % overall for two doses and 98 % for three doses. Abstract: We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE was 89 % (95 % CI 84–93 %) overall, 79 % in patients with more than two comorbidities and 77 % in adults aged 60–75 years. A third dose increased the VE to more than 93 % in all patient-subgroups.